abstract |
The present invention relates to a binding agent that specifically binds human MET, a binding agent that specifically binds one or more components of the WNT pathway, and one or more components of the human MET and WNT pathway. It relates to bispecific agents that bind both, and methods of using agents for treating diseases such as cancer. |